|
Interferon alfa-2a
resources
DRUG INFO
Interferon alfa-2a
Drug Name:
Interferon alfa-2a
|
|
|
Indication: For treatment of chronic hepatitis C, hairy cell leukemia, AIDS-related Kaposi's sarcoma, and chronic myelogenous leukemia
Pharmacology: Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.
Mechanism Of Action: Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.
Drug Category: Antiviral Agents; Antineoplastic Agents
Brand Names/Synonyms: Interferon alpha-2 precursor;Interferon alpha-A;LeIF A; Roferon A (Hoffmann-La Roche Inc)
Dosage Forms: SOLUTION
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Human interferon alpha 2a
Chemical Formula: C860H1353N227O255S9
Half Life: 1.2 hours (mammalian reticulocytes, in vitro)
Drug Type: Approved Drug
# Accession No: BIOD00095
CAS Registry Number: 11/1/9008
| | |
